387 related articles for article (PubMed ID: 25994247)
1. Risk of oral and gastrointestinal mucosal injury in patients with solid tumors treated with everolimus, temsirolimus or ridaforolimus: a comparative systematic review and meta-analysis.
Abdel-Rahman O; Fouad M
Expert Rev Anticancer Ther; 2015; 15(7):847-58. PubMed ID: 25994247
[TBL] [Abstract][Full Text] [Related]
2. Risk of fatigue in patients with solid tumors treated with everolimus, temsirolimus or ridaforolimus: a comparative meta-analysis.
Abdel-Rahman O; Fouad M
Expert Rev Anticancer Ther; 2015 Apr; 15(4):477-86. PubMed ID: 25665062
[TBL] [Abstract][Full Text] [Related]
3. S-1-based regimens and the risk of oral and gastrointestinal mucosal injury: a meta-analysis with comparison to other fluoropyrimidines.
Abdel-Rahman O; ElHalawani H; Essam-Eldin S
Expert Opin Drug Saf; 2016 Jan; 15(1):5-20. PubMed ID: 26513339
[TBL] [Abstract][Full Text] [Related]
4. Oral stomatitis and mTOR inhibitors: A review of current evidence in 20,915 patients.
Lo Muzio L; Arena C; Troiano G; Villa A
Oral Dis; 2018 Mar; 24(1-2):144-171. PubMed ID: 29480626
[TBL] [Abstract][Full Text] [Related]
5. Incidence and risk of high-grade stomatitis with mTOR inhibitors in cancer patients.
Shameem R; Lacouture M; Wu S
Cancer Invest; 2015 Mar; 33(3):70-7. PubMed ID: 25635371
[TBL] [Abstract][Full Text] [Related]
6. Risk of mucocutaneous toxicities in patients with solid tumors treated with everolimus; a systematic review and meta-analysis.
Abdel-Rahman O; Fouad M
Expert Rev Anticancer Ther; 2014 Dec; 14(12):1529-36. PubMed ID: 25159115
[TBL] [Abstract][Full Text] [Related]
7. Hematologic toxicities associated with mTOR inhibitors temsirolimus and everolimus in cancer patients: a systematic review and meta-analysis.
Xu J; Tian D
Curr Med Res Opin; 2014 Jan; 30(1):67-74. PubMed ID: 24028709
[TBL] [Abstract][Full Text] [Related]
8. Risk of selected gastrointestinal toxicities in patients with advanced non-small cell lung cancer receiving erlotinib: a systematic review and meta-analysis.
Abdel-Rahman O; Fouad M
Expert Rev Anticancer Ther; 2015 Apr; 15(4):465-75. PubMed ID: 25664933
[TBL] [Abstract][Full Text] [Related]
9. Meta-analysis of stomatitis in clinical studies of everolimus: incidence and relationship with efficacy.
Rugo HS; Hortobagyi GN; Yao J; Pavel M; Ravaud A; Franz D; Ringeisen F; Gallo J; Rouyrre N; Anak O; Motzer R
Ann Oncol; 2016 Mar; 27(3):519-25. PubMed ID: 26759276
[TBL] [Abstract][Full Text] [Related]
10. Treatment-related fatigue with everolimus and temsirolimus in patients with cancer-a meta-analysis of clinical trials.
Peng L; Zhou Y; Ye X; Zhao Q
Tumour Biol; 2015 Feb; 36(2):643-54. PubMed ID: 25281033
[TBL] [Abstract][Full Text] [Related]
11. Risk of hematologic toxicities in patients with solid tumors treated with everolimus: a systematic review and meta-analysis.
Funakoshi T; Latif A; Galsky MD
Crit Rev Oncol Hematol; 2013 Oct; 88(1):30-41. PubMed ID: 23830806
[TBL] [Abstract][Full Text] [Related]
12. Risk of oral and gastrointestinal mucosal injury in patients with solid tumors treated with ramucirumab: a systematic review and meta-analysis.
Abdel-Rahman O; ElHalawani H
Expert Opin Drug Saf; 2015 Oct; 14(10):1495-506. PubMed ID: 26313327
[TBL] [Abstract][Full Text] [Related]
13. A Phase 1 clinical study of temsirolimus (CCI-779) in Japanese patients with advanced solid tumors.
Fujisaka Y; Yamada Y; Yamamoto N; Horiike A; Tamura T
Jpn J Clin Oncol; 2010 Aug; 40(8):732-8. PubMed ID: 20430774
[TBL] [Abstract][Full Text] [Related]
14. Risk of fatigue and hepatic and metabolic toxicities in patients with solid tumors treated with everolimus: a meta-analysis.
Abdel-Rahman O; Fouad M
Future Oncol; 2015; 11(1):79-90. PubMed ID: 25572784
[TBL] [Abstract][Full Text] [Related]
15. Incidence and risk of rash to mTOR inhibitors in cancer patients--a meta-analysis of randomized controlled trials.
Shameem R; Lacouture M; Wu S
Acta Oncol; 2015 Jan; 54(1):124-32. PubMed ID: 24914484
[TBL] [Abstract][Full Text] [Related]
16. Metabolic complications with the use of mTOR inhibitors for cancer therapy.
Sivendran S; Agarwal N; Gartrell B; Ying J; Boucher KM; Choueiri TK; Sonpavde G; Oh WK; Galsky MD
Cancer Treat Rev; 2014 Feb; 40(1):190-6. PubMed ID: 23684373
[TBL] [Abstract][Full Text] [Related]
17. Risk of selected gastrointestinal toxicities in cancer patients treated with MEK inhibitors: a comparative systematic review and meta-analysis.
Abdel-Rahman O; ElHalawani H; Ahmed H; Ellithy M
Expert Rev Gastroenterol Hepatol; 2015; 9(11):1433-45. PubMed ID: 26365425
[TBL] [Abstract][Full Text] [Related]
18. Incidence and risk of treatment-related mortality with mTOR inhibitors everolimus and temsirolimus in cancer patients: a meta-analysis.
Qi WX; Huang YJ; Yao Y; Shen Z; Min DL
PLoS One; 2013; 8(6):e65166. PubMed ID: 23785409
[TBL] [Abstract][Full Text] [Related]
19. The risk of skin rash and stomatitis with the mammalian target of rapamycin inhibitor temsirolimus: a systematic review of the literature and meta-analysis.
Gomez-Fernandez C; Garden BC; Wu S; Feldman DR; Lacouture ME
Eur J Cancer; 2012 Feb; 48(3):340-6. PubMed ID: 22206873
[TBL] [Abstract][Full Text] [Related]
20. Attributable Risk of Infection to mTOR Inhibitors Everolimus and Temsirolimus in the Treatment of Cancer.
Garcia CA; Wu S
Cancer Invest; 2016 Nov; 34(10):521-530. PubMed ID: 27791402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
